Xgeva

Pharma

Sandoz wins FDA nods for first Prolia, Xgeva biosimilars

Biosimilars to Amgen’s lucrative bone drugs Prolia and Xgeva triumphed at the FDA, though ongoing patent litigation makes the launch timing uncertain.

Fraiser Kansteiner Mar 6, 2024 9:52am

Amgen's Prolia flagged by the FDA for risk of hypocalcemia

Jan 19, 2024 3:35pm

Amgen takes Novartis' Sandoz to court over bone med biosimilar

May 5, 2023 9:35am

Xgeva campaign features patients and life after diagnosis

Mar 4, 2022 10:05am

Bushu and Amgen expand Asian contract manufacturing pact

Nov 24, 2021 11:15am

Amgen rolls Xgeva ad in latest oncology-related TV push

Jan 28, 2019 10:02am